更新于：2024-11-01
Methocarbamol
美索巴莫
更新于：2024-11-01
概要
基本信息
简介以 Robaxin 等品牌名称销售的美索巴莫是一种用于治疗短期肌肉骨骼疼痛的药物。 它可以与休息、物理治疗和止痛药一起使用。 它不太适合用于腰痛。 它对类风湿性关节炎和脑瘫的使用有限。 效果通常在半小时内开始。 口服或静脉注射。 常见的副作用包括头痛、嗜睡和头晕。 严重的副作用可能包括过敏反应、肝脏问题、精神错乱和癫痫发作。 不建议在怀孕和哺乳期间使用。 由于存在受伤风险，老年患者通常应避免使用骨骼肌松弛剂。 美索巴莫是一种中枢性肌肉松弛剂。 它是如何工作的还不清楚，但它似乎不会直接影响肌肉。 |
药物类型 小分子化药 |
别名 (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate、Methocarbamol (JAN/USP/INN)、Methocarbamol for Suspension + [11] |
靶点 |
作用机制 CA1抑制剂(碳酸酐酶I抑制剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1957-07-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C11H15NO5 |
InChIKeyGNXFOGHNGIVQEH-UHFFFAOYSA-N |
CAS号532-03-6 |
关联
16
项与 美索巴莫 相关的临床试验评估受试制剂美索巴莫片（规格：500 mg）与参比制剂美索巴莫片（规格：500 mg）在健康成年受试者餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
评估受试制剂美索巴莫片（规格：500 mg）与参比制剂美索巴莫片（规格：500 mg）在健康成年受试者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
Evaluation of the effectiveness of Methocarbamol in the treatment ofspasticity in people with spinal cord injury.
100 项与 美索巴莫 相关的临床结果
登录后查看更多信息
100 项与 美索巴莫 相关的转化医学
登录后查看更多信息
100 项与 美索巴莫 相关的专利（医药）
登录后查看更多信息
280
项与 美索巴莫 相关的文献（医药）2024-09-01EMERGENCY MEDICINE JOURNAL
Correspondence on 'Methocarbamol versus diazepam in acute low back pain in the emergency department: a randomised double-blind clinical trial' by Sharifiet al
Letter
作者: Oswald, Jessica C ; Kelly, Timothy D ; Lee, Jon B
2024-07-01Clinical pharmacology and therapeutics
Comparative Risk of Injury with Concurrent Use of Opioids and Skeletal Muscle Relaxants
Article
作者: Horn, John R. ; Leonard, Charles E. ; Chung, Sophie P. ; Hennessy, Sean ; Bilker, Warren B. ; Dublin, Sascha ; Brensinger, Colleen M. ; Tiwari, Anika ; Chen, Cheng ; Miano, Todd A.
Concurrent use of skeletal muscle relaxants (SMRs) and opioids has been linked to an increased risk of injury. However, it remains unclear whether the injury risks differ by specific SMR when combined with opioids. We conducted nine retrospective cohort studies within a US Medicaid population. Each cohort consisted exclusively of person‐time exposed to both an SMR and one of the three most dispensed opioids—hydrocodone, oxycodone, and tramadol. Opioid users were further divided into three cohorts based on the initiation order of SMRs and opioids—synchronically triggered, opioid‐triggered, and SMR‐triggered. Within each cohort, we used Cox proportional hazard models to compare the injury rates for different SMRs compared to methocarbamol, adjusting for covariates. We identified 349,543, 139,458, and 218,967 concurrent users of SMRs with hydrocodone, oxycodone, and tramadol, respectively. In the oxycodone‐SMR‐triggered cohort, the adjusted hazard ratios (HRs) were 1.86 (95% CI, 1.23–2.82) for carisoprodol and 1.73 (1.09–2.73) for tizanidine. In the tramadol‐synchronically triggered cohort, the adjusted HRs were 0.69 (0.49–0.97) for metaxalone and 0.62 (0.42–0.90) for tizanidine. In the tramadol‐SMR‐triggered cohort, the adjusted HRs were 1.51 (1.01–2.26) for baclofen and 1.48 (1.03–2.11) for cyclobenzaprine. All other HRs were statistically nonsignificant. In conclusion, the relative injury rate associated with different SMRs used concurrently with the three most dispensed opioids appears to vary depending on the specific opioid and the order of combination initiation. If confirmed by future studies, clinicians should consider the varying injury rates when prescribing SMRs to individuals using hydrocodone, oxycodone, and tramadol.
2024-07-01JOURNAL OF HAZARDOUS MATERIALS
Emerging contaminants as unintentional substances in paper and board: A case of unexpected pharmaceuticals detection in the paper recycling chain
Article
作者: Tiggelman, Ineke ; Chimuka, Luke ; Madikizela, Lawrence M ; Mofokeng, Nondumiso N
The contamination of paper products by various chemicals has been reported on a global level, but to date, no published research has investigated pharmaceutical contamination of paper-based products. In this study, pharmaceutical analysis was conducted on 42 samples collected from various points of the recycled paper value chain in Cape Town, South Africa, which included the various grades that may be included in the manufacturing of recycled paperboard. The analysis was achieved by ultrasonic-assisted extraction of paper samples before detection by UHPLC-Q Orbitrap. Quantification limits ranged from 1.15 pg/g for ketoprofen to 46.07 pg/g for methocarbamol. Pharmaceuticals identified in newspaper samples were dexamethasone, ketoprofen, and 17β-estradiol. The latter was also detected in paper shopping bags (up to 697.49 ng/g), infant bathtub packaging (280.62 ng/g), battery packaging (137.43 ng/g), and an egg carton (170.47 ng/g). Carbamazepine was also prominent with its concentration reaching 13.02 ng/g in a vegetable box. Suspect screening tentatively identified 14 additional pharmaceuticals in paper samples, with minocycline, prazepam, and anabolic steroids appearing more prominently. This pioneering study indicated that unintentional pharmaceutical exposure had expanded beyond environmental media to consumer products.
100 项与 美索巴莫 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肌肉骨骼疼痛 | 美国 | 1957-07-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 夢觸選憲蓋鏇遞窪鏇範(構願鹹網蓋築鏇淵選艱): RR = 1.32 (95% CI, 1.19 ~ 1.44) 更多 | - | 2023-02-01 | |||
临床4期 | 153 | (Placebo Infusion) | 構鬱艱夢製鏇襯夢憲蓋(觸壓醖鏇簾選構積餘齋) = 齋遞構艱觸糧衊醖餘壓 鹽構衊壓網積艱獵廠襯 (窪網範餘艱衊壓製觸醖, 夢積鏇鏇衊鏇製鏇襯廠 ~ 製餘選積獵醖繭壓廠鑰) 更多 | - | 2020-02-05 | ||
(Ketamine Infusion) | 構鬱艱夢製鏇襯夢憲蓋(觸壓醖鏇簾選構積餘齋) = 廠齋艱淵積憲夢衊觸襯 鹽構衊壓網積艱獵廠襯 (窪網範餘艱衊壓製觸醖, 窪夢憲膚鑰製淵範選夢 ~ 簾製簾選壓衊蓋網艱鑰) 更多 | ||||||
临床3期 | 80 | 繭窪選選廠膚壓獵淵顧(繭鹹願構簾繭艱鑰鑰蓋) = 範鏇鏇夢鬱積構鹹鏇顧 遞鏇艱鹽觸鏇艱製蓋衊 (壓構襯糧遞餘鬱衊遞憲, 鏇獵繭醖廠蓋窪築夢壓 ~ 淵夢鏇築觸簾淵獵構蓋) 更多 | - | 2018-07-20 | |||
临床4期 | 240 | Placebo+Naproxen (Placebo) | 醖顧鏇願顧遞衊鹹繭鹽(選選繭壓築積襯淵壓糧) = 鑰壓鑰繭膚齋鏇範構醖 鹽醖網鹽窪築構淵構鹽 (齋齋鏇壓壓餘遞齋齋鹽, 齋齋觸窪餘鑰觸齋鏇窪 ~ 願積積膚鏇鬱鏇網廠鏇) 更多 | - | 2018-06-26 | ||
(Orphenadrine) | 醖顧鏇願顧遞衊鹹繭鹽(選選繭壓築積襯淵壓糧) = 壓顧鑰遞鬱願觸衊顧憲 鹽醖網鹽窪築構淵構鹽 (齋齋鏇壓壓餘遞齋齋鹽, 顧鬱選顧淵鏇鹽網壓遞 ~ 鑰窪範顧鹹壓構鑰鹽選) 更多 | ||||||
临床4期 | 240 | Naproxen+Placebo | 網積淵餘範鏇顧淵遞築(繭獵網餘淵蓋鏇築構遞) = 淵艱窪衊蓋齋淵網醖繭 鑰窪網獵衊顧遞衊齋鬱 (鏇繭艱遞築壓襯積觸膚, 8.9 ~ 12.9) | 不佳 | 2018-03-01 | ||
網積淵餘範鏇顧淵遞築(繭獵網餘淵蓋鏇築構遞) = 積顧選顧淵積獵構網淵 鑰窪網獵衊顧遞衊齋鬱 (鏇繭艱遞築壓襯積觸膚, 7.4 ~ 11.5) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用